PSC
HARP

Piper Sandler & Co’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Piper Sandler & Co’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-58,082
Closed -$563K – 36
2022
Q3 		$563K Buy
+58,082
New +$1.08M 0.46% 17

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Piper Sandler & Co's HARP Position: Q4 2022 in Review

Piper Sandler & Co sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2022, closing a stake of 58,082 shares — an estimated $563K sold.

Piper Sandler & Co first reported a position in HARP in Q3 2022 and held it in 1 quarter. The position peaked at $563K in Q3 2022. 49 funds tracked by Wall St. Rank hold HARP as of Q4 2022.

  • Piper Sandler & Co reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Piper Sandler & Co sold 58,082 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $563K.
  • Piper Sandler & Co first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Piper Sandler & Co's Harpoon Therapeutics, Inc. Common Stock position peaked at $563K in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Piper Sandler & Co's 13F filing for Q4 2022, filed 13 Feb 2023.